• 1
    Slichenmyer WJ,Rowinsky EK,Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993; 85: 271-291.
  • 2
    Burris HA,Fields SM. Topoisomerase I inhibitors. Hematol Oncol Clin North Am. 1994; 8: 333-355.
  • 3
    Slichenmyer WJ,Von Hoff DD. New natural products in cancer chemotherapy. J Clin Pharmacol. 1990; 30: 770-788.
  • 4
    Vassal G,Doz F,Lucchi E, et al. Phase I trial of irinotecan (CPT11) in childhood solid tumors [abstract 896]. Proc Am Soc Clin Oncol. 1997; 16: 253a.
  • 5
    Blaney S,Berg S,Pratt C, et al. A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study [abstract 763]. Proc Am Soc Clin Oncol. 1999; 18: 198a.
  • 6
    Furman WL,Stewart CF,Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 1999; 17: 1815-1824.
  • 7
    Kawato Y,Aonuma M,Hirota Y,Kuga H,Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991; 51: 4187-4191.
  • 8
    Tanizawa A,Fujimori A,Fujimori Y,Pommier Y. Comparison of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 1994; 86: 836-842.
  • 9
    Rothenberg ML,Kuhn JG,Burris HA, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993; 11: 2194-2204.
  • 10
    Kano Y,Suzuki K,Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992; 50: 604-610.
  • 11
    Burris HA,Rothenberg ML,Kuhn JG, et al. Clinical trials with the topoisomerase I inhibitors. Semin Oncol. 1992; 19: 663-669.
  • 12
    Houghton PJ,Cheshire PJ,Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995; 36: 393-403.
  • 13
    Rosenberg B. Platinum complex-DNS interactions and anticancer activity. Biochimie. 1978; 60: 859-867.
  • 14
    Micetich KC,Barnes D,Erickson LC. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum (II) and cis- diamminedichloroplatinum (II) on L1210 cells. Cancer Res. 1985; 45: 4043-4047.
  • 15
    Bacha DM,Caparros-Sison B,Allen JA,Walker R,Tan CTC. Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep. 1986; 70: 865-869.
  • 16
    Gaynon PS,Ettinger LJ,Moel D, et al. Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report. Cancer Treat Rep. 1987; 71: 1039-1042.
  • 17
    Ettinger LJ,Gaynon PS,Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. Cancer. 1993; 73: 1297-1301.
  • 18
    Castleberry RP,Cantor AB,Green AA, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1994; 12: 1616-1620.
  • 19
    Lewis IJ,Stevens MC,Pearson AD,Pinkerton CR,Barnes JM. Carboplatin activity in cisplatin treated neuroblastoma. Prog Clin Biol Res. 1991; 366: 553-559.
  • 20
    Lewis IJ,Stevens MCG,Pearson A,Pinkerton CR,Stevens R. Phase II study of carboplatin in children's tumors [abstract 1413]. Proc Am Soc Clin Oncol. 1993; 12: 412.
  • 21
    Gaynon PS,Lawrence J,Ettinger MD, et al. Carboplatin in childhood brain tumors. Cancer. 1990; 66: 2465-2469.
  • 22
    Friedman HS,Krischer JP,Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1992; 10: 249-256.
  • 23
    Allen JC,Walker R,Luks E,Jennings M,Barfoot S,Tan C. Carboplatin and recurrent childhood brain tumors. J Clin Oncol. 1987; 5: 459-463.
  • 24
    Aquino VM,Fort DW,Kamen BA. Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study. J Neurooncol. 1999; 41: 255-259.
  • 25
    Fukuda M,Oka M,Soda H, et al. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res. 1999; 5: 3963-3969.
  • 26
    Jones SF,Burris HA III, Hainsworth JD, et al.Phase I. Trial of irinotecan plus carboplatin in 2 dose schedules. Oncology (Williston Park). 2003; 17(5 suppl 5 ): 36-40.
  • 27
    Wild CA,Wang SE,Gandara DR, et al. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003; 17(7 suppl 7 ): 11-16.
  • 28
    Yonemori K,Katsumata N,Yamamoto N, et al. A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer. 2005; 104: 1204-1212.
  • 29
    Kinoshita A,Fukuda M,Soda H, et al.Nagasaki Thoracic Oncology Group (NTOG). Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. Br J Cancer. 2006; 94: 1267-1271.
  • 30
    Pillot GA,Read WL,Hennenfent KL, et al. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol. 2006; 1: 972-978.
  • 31
    Sohn JH,Choi HJ,Chang J, et al. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer. 2006; 54: 365-370.
  • 32
    Marina NM,Rodman J,Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol. 1993; 11: 554-560.
  • 33
    Arial N. Validation of a high performance liquid chromatographic mass spectrometric method for the determination of irinotecan, SN-38 and RPR 121056A in human plasma (EDTA). Document Control No. 920013101. Princeton, NJ: Bristol-Myers Squibb Pharmaceutical Research Institute; 2001.
  • 34
    Gaver RC,Allen RG,Marino PI,Peacock RC. Validation of a graphite furnace atomic absorption spectroscopic method for the analysis of platinum in human plasma ultrafiltrate. Document Control No. 910054162. Princeton, NJ: Bristol-Myers Squibb Pharmaceutical Research Institute; 1996.
  • 35
    Cancer Therapy Evaluation Program. Published April 30, 1999. Available at: 4-30-992.pdf. Accessed on April 30, 2007.
  • 36
    Ma MK,Zamboni WC,Radomski KM, et al. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res. 2000; 6: 813-819.
  • 37
    Cosetti M,Wexler LH,Calleja E, et al. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol. 2002; 24: 101-105.
  • 38
    Bisogno G,Riccardi R,Ruggiero A, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer. 2006; 106: 703-707.
  • 39
    Pappo AS,Lyden E,Breitfeld P, et al.Children's Oncology Group. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol. 2007; 25: 362-369.
  • 40
    Bomgaars LR,Bernstein M,Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007; 25: 4622-4627.
  • 41
    Tobinai K,Hotta T,Saito H, et al. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma.CPT-11/Lymphoma Study Group. Jpn J Clin Oncol. 1996; 26: 455-460.
  • 42
    Ohe Y,Sasaki Y,Shinkai T, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst. 1992; 84: 972-974.
  • 43
    Rowinsky EK,Grochow LB,Ettinger DS, et al. Phase I and pharmacological study of the novel topisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino)-carbonyloxy-camptothecan CPT-11 administered as a ninety-minute infusion every 3 weeks [abstract]. Cancer Res. 1994; 54: 427-436.
  • 44
    Crews KR,Stewart CF,Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res. 2002; 8: 2202-2209.